GlassScriptPhysician profile
Rami Arabo
NPI 1578024956
$4,818.91
in general payments reported to CMS, 2019-2025
11 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.76 · 2023: $146 · 2024: $4,346 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,800 · Education: $542 · Food and Beverage: $372 · Travel and Lodging: $77.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,800.00 |
| Education | $542.35 |
| Food and Beverage | $371.80 |
| Travel and Lodging | $77.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $3,985.00 | 2024 | Qinlock |
| Lilly USA, LLC | $198.39 | 2025 | |
| Exelixis INC. | $178.00 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $99.99 | 2025 | Soliris |
| Sobi, INC | $83.99 | 2024 | |
| Beigene USA, INC. | $77.83 | 2022-2024 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $66.94 | 2024 | Onivyde |
| Genzyme Corporation | $49.45 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $46.10 | 2023-2024 | Calquence |
| Janssen Biotech, INC. | $17.58 | 2024 | Rybrevant |
| Janssen Scientific Affairs, LLC | $15.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rami Arabo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.